159 related articles for article (PubMed ID: 22026122)
1. Correlation and in vitro studies on radioactive and nonradioactive albendazole-beta-cyclodextrin complex tablets.
Cetin EO; Ilem D; Gundogdu E; Asikoglu M; Kirilmaz L
Pharmazie; 2011 Sep; 66(9):672-6. PubMed ID: 22026122
[TBL] [Abstract][Full Text] [Related]
2. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
Badr-Eldin SM; Elkheshen SA; Ghorab MM
Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
[TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ
Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129
[TBL] [Abstract][Full Text] [Related]
4. Tablet formulation studies on an oxcarbazepine-beta cyclodextrin binary system.
Patel NV; Chotai NP; Patel MP
Pharmazie; 2008 Apr; 63(4):275-81. PubMed ID: 18468386
[TBL] [Abstract][Full Text] [Related]
5. Molecular simulation of hydroxypropyl-beta-cyclodextrin with hydrophobic selective Cox-II chemopreventive agent using host-guest phenomena.
Sinha VR; Nanda A; Chadha R; Goel H
Acta Pol Pharm; 2011; 68(4):585-92. PubMed ID: 21796941
[TBL] [Abstract][Full Text] [Related]
6. Complexation and solubility behavior of albendazole with some cyclodextrins.
Díaz D; Bernad Bernad MJ; Gracia Mora J; Escobar Llanos CM
Pharm Dev Technol; 1998 Aug; 3(3):395-403. PubMed ID: 9742560
[TBL] [Abstract][Full Text] [Related]
7. Ternary complexation of carvedilol, beta-cyclodextrin and citric acid for mouth-dissolving tablet formulation.
Pokharkar V; Khanna A; Venkatpurwar V; Dhar S; Mandpe L
Acta Pharm; 2009 Jun; 59(2):121-32. PubMed ID: 19564138
[TBL] [Abstract][Full Text] [Related]
8. The influence of the preparation methods on the inclusion of model drugs in a beta-cyclodextrin cavity.
Salústio PJ; Feio G; Figueirinhas JL; Pinto JF; Cabral Marques HM
Eur J Pharm Biopharm; 2009 Feb; 71(2):377-86. PubMed ID: 18977436
[TBL] [Abstract][Full Text] [Related]
9. Preparation and solid-state characterization of bupivacaine hydrochloride cyclodextrin complexes aimed for buccal delivery.
Jug M; Maestrelli F; Bragagni M; Mura P
J Pharm Biomed Anal; 2010 May; 52(1):9-18. PubMed ID: 20004541
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Solubility of Albendazole in Cyclodextrin Inclusion Complex: A Molecular Modeling Approach and Physicochemical Evaluation.
de Melo CG; da Costa LAG; Rabello MM; de Albuquerque Wanderley Sales V; Ferreira AS; da Silva PCD; Nishimura RHV; da Silva RMF; de Araújo Rolim L; Neto PJR
Curr Drug Deliv; 2022; 19(1):86-92. PubMed ID: 34126897
[TBL] [Abstract][Full Text] [Related]
11. Studies on trimethoprim:hydroxypropyl-β-cyclodextrin: aggregate and complex formation.
Garnero C; Zoppi A; Genovese D; Longhi M
Carbohydr Res; 2010 Nov; 345(17):2550-6. PubMed ID: 20933225
[TBL] [Abstract][Full Text] [Related]
12. Improvement of dissolution properties of furosemide by complexation with beta-cyclodextrin.
Ozdemir N; Ordu S
Drug Dev Ind Pharm; 1998 Jan; 24(1):19-25. PubMed ID: 15605593
[TBL] [Abstract][Full Text] [Related]
13. Inclusion complexes of noscapine in beta-cyclodextrin offer better solubility and improved pharmacokinetics.
Madan J; Dhiman N; Parmar VK; Sardana S; Bharatam PV; Aneja R; Chandra R; Katyal A
Cancer Chemother Pharmacol; 2010 Feb; 65(3):537-48. PubMed ID: 19597818
[TBL] [Abstract][Full Text] [Related]
14. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified beta-cyclodextrin.
Figueiras A; Carvalho RA; Ribeiro L; Torres-Labandeira JJ; Veiga FJ
Eur J Pharm Biopharm; 2007 Sep; 67(2):531-9. PubMed ID: 17451924
[TBL] [Abstract][Full Text] [Related]
15. Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin-hydroxypropylmethylcellulose complexes.
Aggarwal S; Singh PN; Mishra B
Pharmazie; 2002 Mar; 57(3):191-3. PubMed ID: 11933849
[TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of orally disintegrating tablets of cilostazol-β-cyclodextrin inclusion complexes.
Desai C; Prabhakar B
Drug Dev Ind Pharm; 2015; 41(10):1589-607. PubMed ID: 25350555
[TBL] [Abstract][Full Text] [Related]
17. Solid-state characterization and dissolution properties of bicalutamide-beta-cyclodextrin inclusion complex.
Patil AL; Pore YV; Kuchekar BS; Late SG
Pharmazie; 2008 Apr; 63(4):282-5. PubMed ID: 18468387
[TBL] [Abstract][Full Text] [Related]
18. Physicochemical, in silico and in vivo evaluation of a danazol-beta-cyclodextrin complex.
Jadhav GS; Vavia PR
Int J Pharm; 2008 Mar; 352(1-2):5-16. PubMed ID: 18023545
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the complexation of albendazole with cyclodextrins for the design of new antiparasitic formulations.
Pradines B; Gallard JF; Iorga BI; Gueutin C; Loiseau PM; Ponchel G; Bouchemal K
Carbohydr Res; 2014 Oct; 398():50-5. PubMed ID: 25240182
[TBL] [Abstract][Full Text] [Related]
20. Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-beta-cyclodextrin complex.
Lv HX; Zhang ZH; Hui-Jiang ; Waddad AY; Zhou JP
Pharmazie; 2012 Jan; 67(1):46-53. PubMed ID: 22393830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
